Thermo Fisher Scientific Inc. (NYSE:TMO) Receives $625.47 Average Price Target from Brokerages

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have received a consensus recommendation of “Moderate Buy” from the twenty-three research firms that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, nineteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $625.4737.

TMO has been the subject of a number of recent analyst reports. TD Cowen boosted their price objective on shares of Thermo Fisher Scientific from $654.00 to $696.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Barclays upped their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Argus upped their target price on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, January 5th.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 10,725 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the transaction, the executive vice president directly owned 18,731 shares in the company, valued at approximately $11,238,600. This trade represents a 36.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 7,250 shares of the business’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $64,400,668.20. The trade was a 5.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 149,271 shares of company stock valued at $86,507,282 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors and hedge funds have recently modified their holdings of TMO. JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter valued at about $28,000. Highline Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after buying an additional 33 shares in the last quarter. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $29,000. Olistico Wealth LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Finally, Capital A Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 66 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Down 0.9%

Thermo Fisher Scientific stock opened at $619.16 on Monday. The business’s fifty day simple moving average is $586.34 and its two-hundred day simple moving average is $523.82. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $232.62 billion, a price-to-earnings ratio of 35.77, a price-to-earnings-growth ratio of 4.11 and a beta of 0.91. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $629.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts predict that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has approved a stock buyback plan on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.